Navigation Links
Silence Therapeutics Patent Update
Date:7/30/2008

ed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer via Quark's license to them of the compound RTP-801i-14 for the treatment of age-related macular degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for Quark's proprietary compound, AKIi-5, which is in a Phase I human clinical study for treatment of acute kidney injury.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About RNAi

RNA interference (RNAi), is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
2. Organizational Changes at Silence Therapeutics
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
7. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
8. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
9. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... V. McCullar, Ph.D., Vice President of Drug,Discovery Operations, ... Investor Summit on Monday, September 15, 2008 at ...
... Data to be Presented at the 7th International ... Symposium on Uveitis ... a leading,developer of antibody fragment therapeutics, today announced that the,company ... lead product candidate, ESBA105, in ophthalmic indications. In,April 2008, ESBATech ...
... PRICING AVAILABLE ... ANYWHERE ... DEMOfall 08 conference here in San Diego, the launch of the,Familybuilder ... $59.95 DNA tests,the most affordable DNA testing available anywhere., At ...
Cached Biology Technology:SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 3
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... 24, 2013 For the first time, scientists at ... moderate-severe traumatic brain injury (TBI), atrophy (shrinkage) in the ... increased physical, social and cognitive stimulation. The ... in the chronic stages of traumatic brain injury," was ...
... (Sept. 24, 2013) Retinal (or fundus) photography is ... cameras can cost tens to hundreds of thousands of ... ophthalmic practices and to physicians in third-world countries. In ... Ear researchers describe the relatively simple technique of fundus ...
... researchers have identified and validated two rare gene mutations that ... that strikes after the age of 60. The two mutations ... enzyme involved in processing the amyloid precursor protein which ... the fifth AD gene overall. In their ...
Cached Biology News:Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 2Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 3Researchers use smart phone photography to diagnose eye disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 3
... DNA-binding protein(DBP). Protein size: ... NP_001343 ELISA titre using peptide based ... for Western Blot: 1.0g/ml in ... HRP conjugated anti-Rabbit IgG should be diluted ...
Porcine Serum US Origin 6 Months or Older...
... DCTD_HUMAN GI Number: 4503277 ... 20016 Description: FUNCTION: Supplies the ... ACTIVITY: dCMP + H 2 O ... SUBUNIT: Homohexamer. SIMILARITY: Belongs to the ...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: